In Neuronal ceroid lipofuscinosis type 2 (TPP1, OMIM 204500), the master switch sits on the ↓ DOWN branch ([F] forced below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: supply). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.
The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.4620, γ 1.3594, spinodal 0.6101). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.
The emergence switch
The switch for Neuronal ceroid lipofuscinosis type 2 is an R19 double-well emerged from the real proximal-promoter DNA of TPP1. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.
emergent axis
↓ DOWN [F]
healthy branch
ON
lesion
LOF_null
γ (stiffness)
1.3594
barrier
0.4620
spinodal
0.6101
s_on / s_off
1.1659 / -1.1659
fragility
0.64
corrective polarity
supply
forced direction
raise s toward ON branch
Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically plausible (barrier 0.462 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.
The derived corrective lever
The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).
Mechanism. supply / restore the positive drive (replace-or-agonise the missing competence)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If supplying/agonising TPP1 (raising the switch drive) does NOT move the DOWN [F] switch toward the healthy branch in a TPP1-deficient model, the h-restore(supply) lever is refuted for this axis.
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual TPP1 allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.
Agents mapped onto the lever
✓ Agreement with established practice. The corrective direction derived here (raise s toward ON branch) independently matches an agent already in clinical use for this disease: recombinant human TPP1 enzyme replacement by INTRACEREBROVENTRICULAR infusion (cerliponase alfa / Brineura, FDA April 2017; 2024 label expanded to all ages incl. presymptomatic) -- DIRECT on the TPP1 gene product, delivered past the blood-brain barrier. The geometry recovered known medicine — this is a validation signal for the logic, not a new treatment claim by this kit.
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
agent (class)
dir.
status
phase
map
recombinant human TPP1 enzyme replacement by INTRACEREBROVENTRICULAR infusion (cerliponase alfa / Brineura, FDA April 2017; 2024 label expanded to all ages incl. presymptomatic) -- DIRECT on the TPP1 gene product, delivered past the blood-brain barrier
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Direction-only candidate leads (corpus join)
Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.
Mechanism. Recombinant human tripeptidyl peptidase-1 delivered by intraventricular enzyme replacement, supplying the lysosomal protease competence that the deficient TPP1 gene product cannot provide. Direction: increase / supply the missing enzymatic competence. Allele scope: agnostic -- the replacement enzyme bypasses the TPP1 lesion. Gene-specific to TPP1 (mapped to neuronal ceroid lipofuscinosis type 2). An expensive intraventricular biologic -- cost and delivery barriers remain -- but it is the approved therapy the supply direction recovers.
✓ This is a rediscovery. Cerliponase alfa (intraventricular recombinant TPP1) is approved for CLN2 disease; recovered by the direction logic. Expensive intraventricular biologic -- cost / delivery barriers remain.
Safety (qualitative; no magnitude). post-marketing safety profile on record (approved for CLN2 disease; device / intraventricular-access signals noted on label; qualitative; no magnitude)
Falsifier. If cerliponase alfa (a gene-specific supply/increase agent) does NOT move the DOWN [F] switch toward the healthy branch in a TPP1-deficient model, the h-restore(supply) direction is refuted for cerliponase alfa here.
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Evidence & provenance
What is reproduced vs. cited for this page.
element
grade
basis
R19 switch & cusp geometry (this page)
[V] verified
emerged from measured promoter γ of TPP1; deterministic, 2×sha256 identical
corrective direction
[F] forced
forced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads
[O] open
direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude
Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).